Approved IBS drug Bentyl may help overcome chemo-resistant prostate cancer
A drug used to treat irritable bowel syndrome (IBS) appears to be effective against prostate cancer in mice when given in tandem with chemotherapy, a new study shows.
A drug used to treat irritable bowel syndrome (IBS) appears to be effective against prostate cancer in mice when given in tandem with chemotherapy, a new study shows.
Ionis Pharmaceuticals’ investigational treatment for hereditary angioedema (HAE) has hit the primary endpoint of a phase 3 trial, allowing the biotech to ready its approval application to the FDA.
The FDA has granted a clearance to its first prescription medical device to help treat low bone density, with a wearable vibrating belt designed for postmenopausal women.
Genentech is walking away from an 18-year relationship with AC Immune, handing back global rights to a pair of Alzheimer’s disease drug candidates after suffering a series of setbacks in the clinic.
Sagimet Biosciences has eased the pain of investors who backed its IPO last year, reporting phase 2b data in metabolic-associated steatohepatitis (MASH) that sent its stock soaring. Yet, the 20% dropout rate in the drug arm and exclusion of patients from the analysis prompted questions from analysts.
As one of the first in a new year wave of biotechs to announce IPO plans, Arrivent Biopharma has now said it expects to raise around $135 million in the company’s upcoming public offering.
Despite having an FDA-approved injectable product, pruritus-focused drug developer Cara Therapeutics is laying off up to half of its staff as it narrows its clinical ambitions.
Just a few weeks after earning a permanent injunction barring the use of Invitae’s Personalized Cancer Monitoring tests, Natera is taking another of the diagnostic developer’s product portfolios off its hands.
The nation’s economy slowed sharply last quarter to a 1.6% annual pace in the face of high interest rates, but consumers — the main driver of economic growth — kept spending at a solid pace
The downshift could mean the Federal Reserve cuts interest rates sooner than had been expected.